| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $2.03 | $121.56 $121.56 (0%) | 🛒 Add to cart |
| 90 | $1.98 | $182.33 $177.81 (2%) | 🛒 Add to cart |
| 120 | $1.88 | $243.11 $226.03 (7%) | 🛒 Add to cart |
| 180 | $1.72 | $364.67 $309.41 (15%) | 🛒 Add to cart |
| 270 | $1.60
Best per pill | $547.00 $431.97 (21%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.61 | $78.36 (0%) | 🛒 Add to cart |
| 60 | $2.28 | $156.72 $136.62 (13%) | 🛒 Add to cart |
| 90 | $2.17 | $235.07 $194.89 (17%) | 🛒 Add to cart |
| 120 | $2.10 | $313.43 $252.15 (20%) | 🛒 Add to cart |
| 180 | $2.05 | $470.15 $368.68 (22%) | 🛒 Add to cart |
| 270 | $2.01
Best per pill | $705.22 $542.48 (23%) | 🛒 Add to cart |
More info:
finast
Finast represents a significant advancement in the management of androgen-related conditions, specifically benign prostatic hyperplasia (BPH) and androgenetic alopecia. As a 5α-reductase inhibitor, it works by systematically reducing the conversion of testosterone to dihydrotestosterone (DHT), the primary androgen implicated in prostate growth and hair follicle miniaturization. The clinical utility of finast extends beyond mere symptom relief, targeting the underlying pathophysiology to provide sustainable, long-term benefits. Its adoption in urological and dermatological practice underscores a shift towards evidence-based, mechanism-driven therapies that prioritize patient quality of life.
avodart
Dutasteride, marketed as Avodart, represents one of the more interesting developments in urological pharmacotherapy over the past two decades. As a 5α-reductase inhibitor, it occupies a unique position in managing benign prostatic hyperplasia, though its applications have expanded beyond initial indications. What began as another option for BPH has revealed complexities in androgen pathway modulation that continue to surprise clinicians. Avodart: Effective BPH Symptom Management Through Dual Enzyme Inhibition 1. Introduction: What is Avodart?
cardura
Cardura, known generically as doxazosin, is an alpha-1 adrenergic blocker primarily used to manage hypertension and benign prostatic hyperplasia. It works by relaxing blood vessels and prostate/urethral smooth muscle. This monograph examines its clinical profile, evidence base, and practical applications. Cardura: Effective Blood Pressure and Urinary Symptom Control - Evidence-Based Review 1. Introduction: What is Cardura? Its Role in Modern Medicine Cardura belongs to the quinazoline class of alpha-1 adrenergic antagonists.
doxazosin
Doxazosin is an alpha-1 adrenergic receptor antagonist primarily used in clinical practice for managing hypertension and benign prostatic hyperplasia (BPH). It belongs to the quinazoline class and works by selectively blocking alpha-1 receptors in vascular smooth muscle and the prostate, leading to vasodilation and relaxation of bladder neck and prostatic smooth muscle. Available in both standard and extended-release formulations, doxazosin offers flexibility in dosing and is often considered when patients have comorbid conditions like BPH and hypertension.
dutas
Dutasteride, marketed under brand names like Avodart and more recently in generic formulations, represents a significant advancement in the management of androgen-related conditions, particularly benign prostatic hyperplasia (BPH) and male pattern hair loss. As a potent 5α-reductase inhibitor, it works by systematically reducing the conversion of testosterone to its more active metabolite, dihydrotestosterone (DHT), which is implicated in prostate growth and hair follicle miniaturization. This dual-action mechanism has positioned dutasteride as a cornerstone in urological and dermatological therapeutics, offering patients a non-surgical option to address both urinary symptoms and cosmetic concerns related to androgen sensitivity.
Finpecia: Clinically Proven Hair Regrowth for Male Pattern Baldness - Evidence-Based Review
Finpecia is the brand name for finasteride 1mg tablets, a medication specifically developed for the treatment of male pattern hair loss (androgenetic alopecia). It represents one of the only two FDA-approved oral medications for this condition, occupying a critical space in dermatology and men’s health. Unlike topical treatments that work locally, Finpecia operates systemically to address the hormonal root cause of hair loss. 1. Introduction: What is Finpecia? Its Role in Modern Medicine Finpecia contains finasteride 1mg as its active pharmaceutical ingredient, classified as a type II 5α-reductase inhibitor.
flomax
Flomax, known generically as tamsulosin hydrochloride, is a selective alpha-1 adrenergic receptor antagonist specifically formulated for the treatment of benign prostatic hyperplasia (BPH). It belongs to a class of medications that target the smooth muscle in the prostate and bladder neck, facilitating improved urinary flow. Its development marked a significant advancement in urological therapeutics due to its targeted mechanism, which minimizes the cardiovascular side effects commonly associated with non-selective alpha-blockers. Flomax is typically administered in a controlled-release capsule, ensuring steady plasma concentrations for sustained symptomatic relief.
Himplasia: Clinically Validated Herbal Support for Benign Prostatic Hyperplasia - Evidence-Based Review
Himplasia represents one of those interesting interventions that sits right at the intersection of traditional herbal wisdom and modern clinical practice. It’s a proprietary herbal formulation developed by Himalaya Drug Company, specifically indicated for benign prostatic hyperplasia (BPH). What makes it clinically relevant isn’t just the traditional use but the growing body of evidence supporting its mechanism and efficacy. I’ve been using it in my urology practice for about eight years now, initially skeptical but increasingly impressed with its role in managing early to moderate BPH symptoms.
Minoxytop: Advanced Topical Solution for Androgenetic Alopecia - Evidence-Based Review
Minoxytop represents a novel topical formulation combining 5% minoxidil with a proprietary penetration-enhancing complex, specifically engineered to overcome the limitations of traditional minoxidil solutions in androgenetic alopecia management. Unlike conventional preparations that often cause significant scalp irritation and deliver inconsistent absorption, this medical device utilizes a targeted delivery system that stabilizes the active ingredient while improving follicular uptake. The development team, which I had the privilege of consulting with during Phase III trials, focused on creating a formulation that would address the two primary reasons for treatment discontinuation: local adverse effects and perceived lack of efficacy.